Rhythm Pharmaceuticals, Inc.RYTM
What Rhythm Pharmaceuticals, Inc. does.
We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE ® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subset of individuals who have hyperphagia, a pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, decreased energy expenditure and severe obesity due to diseases such as acquired or congenital hypothalamic obesity, Bardet-Biedl syndrome (BBS), Prader-Willi syndrome (PWS) and other diseases caused by impaired MC4R pathway signaling. The MC4R pathway is a neuro-endocrine pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight. IMCIVREE, our most advanced MC4R agonist for which we hold worldwide rights, is the first-ever therapy that is marketed in the United States, European Union (EU), United Kingdom, Canada and several other countries and regions for certain rare MC4R pathway diseases, including BBS. We also are developing two earlier-stage investigational MC4R agonists, bivamelagon (formerly LB54640), an oral small molecule, and RM-718, designed for weekly subcutaneous administration. These investigational assets, for which we possess global rights, are specifically designed to exhibit high selectivity for MC4R while functionally sparing MC1R. As a result, they are not expected to induce hyperpigmentation.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $3.2M | $23.6M | $77.4M | $130.1M | $189.8M |
| Net income | -$134.0M | -$69.6M | -$181.1M | -$184.7M | -$260.6M | -$196.5M |
| Free cash flow | -$122.2M | -$146.4M | -$173.7M | -$136.2M | -$113.9M | -$116.6M |
More on RYTM.
- Rhythm Pharmaceuticals, Inc. summary
- Rhythm Pharmaceuticals, Inc. financial statements
- Rhythm Pharmaceuticals, Inc. key metrics
- Rhythm Pharmaceuticals, Inc. health scores and style box
- Rhythm Pharmaceuticals, Inc. earnings
- Rhythm Pharmaceuticals, Inc. dividends
- Rhythm Pharmaceuticals, Inc. valuation
- Rhythm Pharmaceuticals, Inc. ownership and insiders
- Rhythm Pharmaceuticals, Inc. peers
Figures from Rhythm Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.